Jazz Pharmaceuticals plc files 8-K covering a debt obligation
The drugmaker filed an 8-K on 2026-08-31 reporting events including entry into a material agreement and creation of a direct financial obligation.
Jazz Pharmaceuticals plc, a pharmaceutical preparations company listed on Nasdaq under ticker JAZZ, filed an 8-K with the SEC on 2026-08-31.[1][2]
The filing carries an accession number of 0001193125-26-377073 and covers a period ending 2026-08-26.[1]
The 8-K reports items 1.01, 2.03, 3.02, 8.01 and 9.01, the second of which concerns the creation of a direct financial obligation.[1]
The company's CIK is 0001232524.[1][2]
A prior filing record dated 2026-08-09 is no longer available in the register.[3]